Form 8-K - Current report:
SEC Accession No. 0001213900-25-029639
Filing Date
2025-04-08
Accepted
2025-04-08 09:00:08
Documents
15
Period of Report
2025-04-08
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0237471-8k_oncon.htm   iXBRL 8-K 25688
2 PRESS RELEASE, DATED APRIL 8, 2025 ea023747101ex99-1_oncon.htm EX-99.1 13003
3 GRAPHIC ex99-1_001.jpg GRAPHIC 13955
  Complete submission text file 0001213900-25-029639.txt   238918

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE onco-20250408.xsd EX-101.SCH 3041
5 XBRL LABEL FILE onco-20250408_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE onco-20250408_pre.xml EX-101.PRE 22376
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0237471-8k_oncon_htm.xml XML 3795
Mailing Address 201 E. FIFTH STREET SUITE 1900 CINCINNATI OH 45202
Business Address 201 E. FIFTH STREET SUITE 1900 CINCINNATI OH 45202 513-620-4101
Onconetix, Inc. (Filer) CIK: 0001782107 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41294 | Film No.: 25820414
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)